Church of PeptidesSearch
Portrait of CJC + Ipamorelin
The Choirs · Unapproved combination

CJC + Ipamorelin

The Heralds

Ipamorelin: Denmark, 1998 · CJC-1295: Montreal, Canada, 2000s

CJC-1295 and ipamorelin stimulate growth-hormone signaling through different receptors. Their pairing is an unapproved combination; a change in hormone levels does not establish better recovery, body composition or health.

Evidence ladder: Unsupported claimCombination: controlled human benefit not establishedEducational record
ClassificationThe Choirs
Evidence summaryCombination: controlled human benefit not established
OriginIpamorelin: Denmark, 1998 · CJC-1295: Montreal, Canada, 2000s
Book of the Canon · Comic scripture

The laboratory legend

One Herald rang the bell; the other opened the gate. By breakfast the whole growth-hormone wing was awake and asking who authorized a duet before safety review.

This bold passage is invented comedy, not scientific or historical fact.
Documented history

Where the story actually begins

Ipamorelin was described by Novo Nordisk researchers in Denmark in 1998 as a selective growth-hormone secretagogue. CJC-1295 was developed by Montreal-based ConjuChem and entered human studies in the 2000s as a long-acting GHRH analog. Their popular pairing is a later practice, not an FDA-approved combined product.

Ipamorelin: Denmark, 1998 · CJC-1295: Montreal, Canada, 2000s
Component bookCJC-1295 →Component bookIpamorelin →
Scientific record

What the evidence says

Roles or demonstrated benefits

  • Both can stimulate the growth-hormone/IGF-1 axis through different receptors.
  • Small studies established pharmacodynamic activity for CJC-1295.
  • A biologic response does not establish anti-aging, recovery, or body-composition benefit.

Risks, side effects, and limits

  • The combination lacks FDA approval and robust controlled outcome trials.
  • GH/IGF-1 stimulation may relate to edema, joint symptoms, glucose changes, or other risks.
  • Combined long-term safety, optimal formulation, and product quality remain uncertain; both are prohibited in sport.
Doctide’s verdict

The Heralds can ring different bells in the same hormonal system. Until the duet has its own convincing outcome and safety studies, coordination is a mechanism—not a clinical verdict.

Editorial recordProfile editorial revision: October 4, 2026Prepared under the Church of Peptides evidence standardEditorial review: Church of PeptidesIndependent clinical review: none to dateContent evidence reviewed: September 14, 2026
Evidence ledger

Sources

  1. Ipamorelin 1998 paper
  2. CJC-1295 human study
  3. WADA prohibited list

Fiction disclosure: The bold laboratory legend above is invented. The historical and scientific sections are intended as sourced summaries; no invented connective events were added to the documented history.

Educational entertainment only. Not medical advice, diagnosis, dosing guidance, or a recommendation to obtain or use a product.